Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE: ABBV ). Supporting his choice, Canaccord Genuity analyst Gary Nachman maintained AbbVie with a Buy rating on Wednesday and raised the price target from $273 to $282.